Demystifying the Canadian Drug and Health Products Regulatory Landscape

Topics

• Major initiatives and up-coming changes in the regulatory environment, including use of foreign reviews / decisions, international collaboration, improved access to different drugs, expansion of priority review pathways, the use of real-world evidence, the Medical Device Single Audit Program, and the digital health review division
• Current regulatory & submission requirements for drugs, biologics and medical devices as required by Canada`s Regulatory Agency, Health Canada
• Best approaches for working with Health Canada in any drug and & health product development plan

Who should Attend

• Pharma
• Regulatory
• Decision Makers
• Biotech Executives